SystImmune Inc. clinical trial pipeline

3 trials changed in the last 30 days: 2 stopped, 1 with a notable change, 0 with minor changes only.

1. Stopped

   Profile, Efficacy of Bl-M11D1

   Trial terminated

   Also in this update: Final enrollment: 52 participants (planned 120); Primary completion date changed from estimate of Dec 31, 2026 to Sep 16, 2026

   SystImmune Inc.·Phase 1· NCT06714591· Registry history of NCT06714591 on ClinicalTrials.gov (opens the registry)

   Sep 24, 2026

2. Stopped

   BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or…BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

   Trial terminated

   Also in this update: Final enrollment: 3 participants — 3% of the 120 planned; Primary completion date changed from estimate of Sep 1, 2027 to Jan 30, 2026

   SystImmune Inc.·Phase 1· NCT06714617· Registry history of NCT06714617 on ClinicalTrials.gov (opens the registry)

   Sep 22, 2026

3. Notable

   BL-B01D1 · Metastatic or Unresectable Non-Small Cell Lung Cancer…BL-B01D1 · Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

   Primary completion pushed from Dec 31, 2026 to Apr 20, 2030

   Also in this update: Enrollment increased: 470 → 540 participants; Study completion pushed from Mar 21, 2028 to Jul 22, 2030

   SystImmune Inc.·Phase 1· NCT05983432· Registry history of NCT05983432 on ClinicalTrials.gov (opens the registry)

   Sep 21, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.